

Contact: Sanjeev Luther
Chief Business Officer, Cornerstone Pharmaceuticals, Inc.
Sanjeev@cornerstonepharma.com

Kara Golub
Vice President, JFK Communications, Inc.
609-456-0822
kgolub@jfkhealth.com

Cornerstone Pharmaceuticals to Present New Data on CPI-613 at the American Society of Hematology 2016 Annual Meeting

New Data Highlight CPI-613 in Acute Myeloid Leukemia (AML) and Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma (T-cell NHL)

CRANBURY, NEW JERSEY (November 21, 2016) –

WHAT: CPI-613 is Cornerstone Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways in cancer cells by targeting mitochondrial metabolism. It selectively targets the mitochondrial tricarboxylic acid (TCA) cycle, a process essential to tumor cell proliferation and survival. The two datasets are from the first reported studies of CPI-613-based combination therapies in patients with AML and T-cell NHL.

ASH Abstract Details:

- **TCA Cycle Inhibition by CPI-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)**
 - **Date/Time:** Monday, December 5, 2016 6:00-8:00 PM PT
 - **Session:** 616. Acute Myeloid Leukemia: Novel Therapy, Excluding Transplantation: Poster III
 - **Location:** San Diego Convention Center, Hall GH
 - **Abstract #:** 4062
 - **Scheduled Presenter:** Timothy S. Pardee, M.D. Ph.D., Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Winston-Salem, N

- **Phase I Dose-Escalation Study of CPI-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma**

- **Date/Time:** Monday, December 5, 2016, 6:00-8:00 PM PT
- **Session:** 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III
- **Location:** San Diego Convention Center, Hall GH
- **Abstract #:** 4163
- **Scheduled Presenter:** Zanetta S. Lamar, M.D., Department of Hematology / Oncology, Wake Forest Baptist Medical Center, Winston-Salem, NC

WHO: Drs. Pardee and Lamar (primary investigators) will be available for media interviews upon request

WHERE: American Society of Hematology Annual Meeting, San Diego Convention Center, San Diego, California

CONTACT: Kara Golub, 609-456-0822 or kgolub@jfkhealth.com, for more information.

About Cornerstone Pharmaceuticals, Inc.

Cornerstone Pharmaceuticals, Inc. is a privately held, clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's investors include IDT Corporation (NYSE: IDT). Cornerstone's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Cornerstone's first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has designated CPI-613 an orphan drug for the treatment of acute myeloid leukemia (AML), pancreatic cancer and myelodysplastic syndromes (MDS). www.cornerstonepharma.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements relate to future events or the company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the

uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

###